LYTENAVA
- Product NDC
- 82491-025
- 11-digit product format
- 824910025
- Labeler code
- 82491
- Product ID
- 82491-025_c4cac030-d1d8-4bb1-a38c-c1e2e91f002d
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- bevacizumab-vikg
- Dosage form
- INJECTION
- Route
- INTRAVITREAL
- Labeler
- Outlook Therapeutics, Inc.
- Application
- BLA761320
- Marketing category
- BLA
- Marketing start
- 2026-07-16
- Substance
- BEVACIZUMAB
- Active strength
- 1.25 mg/1
- Pharmacologic classes
- Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- LYTENAVA
- Listing expiration
- 2027-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| BEVACIZUMAB | 1.25 mg/1 |
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 761320 | Lytenava | bevacizumab-vikg | 351(a) | Rx | 2026-09-01 |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|
| 82491-025-10 | 82491002510 | 1 VIAL, GLASS in 1 CARTON (82491-025-10) / 1 INJECTION in 1 VIAL, GLASS | 2026-07-16 | No | No | Current |